iShares MSCI Taiwan ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $100.52, while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWT | HRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $2.02 |
52-Week Low | $58.05 | $0.39 |
Market Cap | — | $84.50M |
Enterprise Value | — | $182.40M |
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $100.60, down 1.26% on the day amid neutral technical signals. The ETF has delivered exceptional performance with a 100%+ gain in 2026, driven by Taiwan's dominant semiconductor sector and AI infrastructure exposure. Current technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support levels cluster around $99-$101.
The outlook remains favorable given Taiwan's critical role in global semiconductor supply chains and AI infrastructure growth, though stretched valuations and geopolitical tensions with China present significant risks. Institutional interest remains strong due to concentrated exposure to TSMC and other tech leaders, but investors should monitor dollar movements and regional stability.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Trailing returns across standard periods
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →